Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | FPR3 | P25089 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14919306 | 1.00 | CYP2D6 (0.42) | CYP2D6FDPSDRD2DRD3FPR3 | |
| SCHEMBL3335001 | 1.00 | CYP2D6 (0.42) | CYP2D6FDPSDRD2DRD3FPR3 | |
| Hydrochloric Acid SCHEMBL27126809 | 0.98 | DRD2 (0.41) | CYP2D6FDPSDRD2DRD3FPR3 | |
| Hydrochloric Acid SCHEMBL27007558 | 0.98 | DRD2 (0.41) | CYP2D6FDPSDRD2DRD3FPR3 | |
| SCHEMBL3088560 | 0.94 | FDPS (0.47) | CYP2D6FDPSMEN1KMT2AMITF | |
| SCHEMBL1598094 | 0.94 | FDPS (0.47) | CYP2D6FDPSMEN1KMT2AMITF | |
| SCHEMBL20186812 | 0.94 | FDPS (0.47) | CYP2D6FDPSMEN1KMT2AMITF | |
| Hydrochloric Acid SCHEMBL17114350 | 0.92 | FDPS (0.46) | CYP2D6FDPSMEN1KMT2AMITF | |
| SCHEMBL17513288 | 0.85 | — | — | |
| SCHEMBL23201076 | 0.85 | DRD2 (0.39) | CYP2D6FDPSDRD2DRD3FPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2024-02-01 | — | — | US | disclosed |
| WO-2023137406-A1 | HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND METHODS OF USING SAME | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023086438-A1 | PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-104379560-A | Benzamide derivative | CHUGAI PHARMACEUTICAL CO LTD | 2015-02-25 | — | — | CN | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | CYP2D6 2635/4885FDPS 2560/4885DRD2 3478/4885 |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | CYP2D6 490/4885FDPS 1267/4885DRD2 1092/4885 |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | CYP2D6 79/4885FDPS 1422/4885DRD2 932/4885 |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | CYP2D6 902/4885FDPS 251/4885DRD2 2886/4885 |
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | CYP2D6 4191/4885FDPS 3240/4885DRD2 3915/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | CYP2D6 2809/4885FDPS 2512/4885DRD2 3676/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | CYP2D6 158/4885FDPS 683/4885DRD2 120/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | CYP2D6 51/4885FDPS 3006/4885DRD2 38/4885 |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | CYP2D6 2283/4885FDPS 87/4885DRD2 3554/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | CYP2D6 2809/4885FDPS 2512/4885DRD2 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.